Bhubaneswar: National Technical Advisory Group on Immunization (NTAGI) has approved Serum Institute of India’s COVID-19 vaccine Covovax for the 12-17 age group, sources told news agency ANI on Friday.
Notably, an expert panel of the country’s central drug authority recommended granting emergency use authorisation (EUA) to Covovax for this age group subject to certain conditions, on March 9. Subsequently, the Pune-based firm started to pursue regulatory permissions and its protocol.
Covovax has been developed through a technology transfer protocol from Novavax, which already has approval from the European medicines agency for conditional marketing authorisation.
India began inoculating children aged 12-14 on March 16 with Biological E’s Corbevax.
Mettur: K Padmarajan, the 65-year-old tyre repair shop owner in Tamil Nadu’s Mettur who has…
Bhubaneswar: Bharatiya Janata Party (BJP) is likely to announce party candidates for the remaining three…
New Delhi: Ahead of the elections, the centre on Thursday notified wage rate hike, ranging…
Cuttack: Cuttack Lok Sabha constituency may witness a battle between political stalwart Bhartruhari Mahatab and…
Bhubaneswar: With major political parties gearing up for the upcoming elections in Odisha, the silk…
Coimbatore: Erode MP and senior MDMK leader A Ganeshamurthi, who allegedly attempted suicide a few…
Kendrapada: Days after joining the ruling BJD, Anshuman Mohanty is believed to be not keen…
Balangir: At least 20 people were stated to be critical after playing Holi with hazardous…